Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

IFA significantly attenuated capsule-mediated resistance to the binding of C3b and C5b-9 to bacterial surface. by Tingting Wang (123983)

Subjects:

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Mean standard errors across time points for the outcome of social stigma. by Ana Beato (20489933)

Means with standard errors across time points for the outcome of social distance. by Ana Beato (20489933)

Means with standard errors across time points for the outcome of intergroup anxiety. by Ana Beato (20489933)

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Means with standard errors across time points for the outcome of mental health knowledge. by Ana Beato (20489933)

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. The gray points represent miRNAs with no significant change (p < 0.05, false discovery rate (FDR) q < 0.05), while red and blue points indicate upregulated and downregulated miRNAs (p < 0.05, FDR q < 0.05), respectively. …”

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (sign... by Mobina Faqani (22783963)